The short answer
In the UAE, Ozempic is approved and supplied as a treatment for type 2 diabetes. At Endocare, we prescribe Ozempic for weight loss only when the patient is diabetic or pre-diabetic. If you do not meet that criterion, the appropriate semaglutide for weight loss is Wegovy, which is approved in the UAE for chronic weight management. Both medications contain the same active ingredient, but they are licensed for different uses, and the right choice depends on your blood work.
Key takeaways:
- Ozempic is semaglutide indicated for type 2 diabetes in the UAE. It is prescribed for weight loss only in diabetic or pre-diabetic patients.
- Wegovy is semaglutide indicated for chronic weight management. For non-diabetic patients, it is the on-label option.
- An endocrinologist confirms which one applies after blood tests, body-composition analysis, and a full medical history.
- Insurance reimbursement in the UAE generally requires a qualifying diabetes or pre-diabetes diagnosis. Wegovy for weight loss is typically self-pay.
- Self-sourcing Ozempic without medical supervision is not safe practice. There is no dose plan, no monitoring, and no follow-up.
What Ozempic is approved for in the UAE
Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist that helps regulate appetite, slows stomach emptying, and improves the body’s response to insulin. What separates them is what each medication is licensed to treat.
- Ozempic is licensed in the UAE for adults with type 2 diabetes mellitus, to improve blood sugar control. Available doses in the UAE start at 0.25 mg and go up to 1.0 mg once a week.
- Wegovy is licensed in the UAE for chronic weight management. Doses run from 0.25 mg up to 2.4 mg once a week.
Same molecule. Two different licensed products. That difference is not just regulatory paperwork. It is what determines which medication a doctor can responsibly prescribe for which patient. For more on the molecule itself, see semaglutide as a molecule.
What ‘pre-diabetic’ actually means, and why it matters
Pre-diabetes is a blood sugar state that sits above normal but below the threshold for type 2 diabetes. It is defined primarily by HbA1c, the three-month average of blood sugar.
- Normal HbA1c: below 5.7%.
- Pre-diabetes HbA1c: 7% to 6.4%.
- Type 2 diabetes HbA1c: 6.5% or higher.
It matters here because Ozempic is appropriate for patients in either of the higher two ranges, where the medication is being used for its licensed glucose-lowering effect, with weight loss as a clinically welcome secondary benefit. For patients with normal HbA1c, the picture is different. Even if a patient is overweight or has obesity, the absence of any glucose abnormality means the case for Ozempic is no longer ‘treating diabetes with a useful weight-loss effect’. It would be ‘using a diabetes medication purely for weight loss’, which is not the right framing in the UAE regulatory context, and not how we prescribe at Endocare.
Many patients only discover their HbA1c status during their first specialist consultation. It is not unusual for a patient to come in expecting a Wegovy prescription, run a full blood panel, and discover they actually have pre-diabetes, which then shifts the recommendation toward Ozempic. The opposite also happens. The blood test, not the search query, is what decides. Patients whose blood work places them in the pre-diabetes range often benefit from Endocare’s prediabetes weight-loss programme alongside any GLP-1 prescription.
If you are not diabetic, the right semaglutide is Wegovy
For non-diabetic patients who meet the BMI criteria for medical weight loss, the appropriate semaglutide in the UAE is Wegovy. It is the same molecule with a licensed indication for chronic weight management, and it has its own dose range built specifically for that purpose.
- Eligibility: BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related condition such as hypertension, dyslipidaemia, or polycystic ovarian syndrome.
- Average weight loss: around 12 to 15% of starting body weight over 12 months in clinical trials, when paired with structured lifestyle support.
- Dosing: starts at 0.25 mg once a week and steps up gradually as tolerated.
- UAE supply: prescribed at Endocare with same-day delivery in Dubai and within 48 hours UAE-wide, with no markup on pharmacy price.
Read more about Wegovy at Endocare.
For patients who need a larger magnitude of weight loss, or who do not respond well to semaglutide, Mounjaro (tirzepatide) injection at Endocare is an alternative GLP-1 option with average weight loss of around 20% at six months at the top dose. And for patients specifically asking about an oral GLP-1 pill rather than an injection, Foundayo (orforglipron), Endocare’s oral GLP-1 option, is now available in the UAE. Injectable semaglutide also has direct cardiovascular outcome data in patients with established cardiovascular disease and overweight or obesity, from the SELECT trial.
Off-label prescribing: what an endocrinologist will and will not do
Off-label prescribing exists in medicine, and is sometimes appropriate. Doctors prescribe approved medications for unapproved indications in well-defined cases, often when published evidence supports the use and licensed alternatives are unsuitable.
Where Ozempic is concerned in the UAE, two things are true at once. The same active ingredient, semaglutide, has an on-label, licensed product specifically for weight management. That product is Wegovy. So the case for using Ozempic off-label as a weight-loss medication in non-diabetic patients does not hold, because there is no clinical need to step outside the label when the label-correct option already exists.
That is the position at Endocare. Ozempic is prescribed for weight loss only when the patient is diabetic or pre-diabetic. For non-diabetic patients, Wegovy is the right semaglutide. For patients who specifically want a different molecule, Mounjaro is an option. The decision is medical. Read more on Ozempic for diabetic and pre-diabetic patients.
Comparing Ozempic and Wegovy at a glance
| Feature | Ozempic | Wegovy |
| Active ingredient | Semaglutide | Semaglutide |
| UAE indication | Type 2 diabetes | Chronic weight management |
| Dose range in the UAE | 0.25 to 1.0 mg weekly | 0.25 to 2.4 mg weekly |
| Weight-loss eligibility at Endocare | Diabetic or pre-diabetic patients | BMI 30+ or 27+ with a weight-related condition |
| Insurance in the UAE | Often reimbursable with diabetes diagnosis | Typically self-pay |
For deeper reading on the two products side by side, see the full Ozempic vs Wegovy comparison.
What your first endocrinologist visit at Endocare looks like
The honest answer to ‘can I get Ozempic for weight loss’ is decided in a clinic, as part of your first consultation. Here is what happens during the first specialist consultation at Endocare.
- Medical history. Personal and family history of diabetes, cardiovascular disease, thyroid conditions, gastrointestinal conditions, pregnancy plans, prior weight-loss attempts, and current medications.
- Recent blood tests. A blood panel within the past three months is required before any GLP-1 prescription. If no recent labs are on file, Endocare can arrange an at-home blood draw. The panel typically includes HbA1c, fasting glucose, lipid profile, thyroid function, liver function, kidney function, and where relevant, vitamin and mineral status.
- Body-composition analysis. Every patient gets a body-composition scan, included free of charge with every consultation, for every patient, on every visit. The scan reports body fat percentage, visceral fat, skeletal muscle mass, and body water.
- Clinical assessment. The endocrinologist reviews everything together, identifies any conditions that need addressing in parallel, and explains which medication makes clinical sense for the patient’s profile.
- Plan and dosing. If a GLP-1 medication is appropriate, the specialist sets a starting dose and an escalation plan, and explains expected side effects and what to do about them.
- Lifestyle support. The medical plan is paired with structured lifestyle coaching led by our weight-loss nutritionist. Coaching covers nutrition, movement, sleep, and stress, with practical tips, swaps, and recipes that fit the patient’s actual routine.
Patients can book a GLP-1 weight-loss consultation online, with the support of Endocare’s doctor-led medical weight-loss programme.
Insurance reality in the UAE
Insurance coverage for GLP-1 medications in the UAE is narrower than many patients expect. Three points are useful to know up front.
- Consultations and laboratory tests can be reimbursable depending on the patient’s specific conditions aside from obesity, as well as the network and benefits of their insurance plan. Patients should check directly with their insurer.
- GLP-1 medications can typically only be reimbursed when prescribed for a qualifying diabetes or pre-diabetes diagnosis. Ozempic prescribed for diabetes is one of the more commonly covered scenarios. Most patients pay GLP-1 medications out of pocket, while higher-tier insurances may cover them.
- Endocare provides the documents needed for an insurance claim after the consultation. Reimbursement is never guaranteed by the clinic, since the final decision rests with the insurer.
Why self-sourcing Ozempic without supervision is not the answer
Patients sometimes ask whether they can simply buy Ozempic privately, online or through informal channels, and use it for weight loss. This is not a route Endocare can support, and it is not just about regulation. It is about safety.
- No assessment. Without a thorough medical evaluation, there is no way to confirm eligibility or rule out contraindications.
- No dose plan. GLP-1 medications are escalated gradually to limit nausea, vomiting, and other gastrointestinal side effects. Skipping that escalation increases tolerability problems and adherence drop-out.
- No monitoring. Without scheduled labs and check-ins, side effects, micronutrient depletion, and muscle loss can go unnoticed. Hair shedding, energy drops, and changes in mood are easier to address when they are caught early.
- No follow-up plan. The medication phase is only part of the picture. The transition off medication, with structured lifestyle support, is what protects against weight regain. Self-sourcing skips that entirely.
Frequently asked questions
Can I get Ozempic for weight loss if I’m not diabetic in Dubai?
At Endocare, no. Ozempic is approved in the UAE for type 2 diabetes and is prescribed for weight loss only when the patient is diabetic or pre-diabetic. For non-diabetic patients, the on-label semaglutide for weight loss is Wegovy.
What is the difference between Ozempic and Wegovy?
Both contain the same active ingredient, semaglutide, and work the same way in the body. The difference is the licensed indication. In the UAE, Ozempic is licensed for type 2 diabetes, with doses up to 1.0 mg weekly. Wegovy is licensed for chronic weight management, with doses up to 2.4 mg weekly. Insurance treatment also differs because the indications differ.
What blood tests does Endocare run before prescribing a GLP-1?
A blood panel within the past three months is required before any GLP-1 prescription. The panel typically includes HbA1c, fasting glucose, lipid profile, thyroid function, liver function, kidney function, and where relevant, vitamin and mineral status. If no recent labs are available, Endocare can arrange an at-home blood draw at a flat fee.
Will my insurance cover Wegovy for weight loss?
Usually not, unless the patient has a qualifying diabetes or pre-diabetes diagnosis. Coverage of consultations and labs depends on the patient’s specific conditions aside from obesity, as well as the network and benefits of their plan.
What if I want a GLP-1 pill instead of an injection?
Foundayo (orforglipron) is an oral GLP-1 pill now available at Endocare in the UAE, taken once a day, with or without food. Average weight loss with Foundayo is in a similar range to injectable semaglutide options at the higher doses. The right choice between Foundayo, Wegovy injection, and Mounjaro injection is decided during your consultation based on your medical picture, not on convenience alone.
Final word from Endocare
Asking ‘can I get Ozempic without diabetes’ is a reasonable question, and a common one in the UAE. The honest answer in our clinic is that Ozempic is the right medication for the right patient, and that patient has a glucose abnormality. For patients without diabetes who want medical help with weight loss, Wegovy is the on-label semaglutide, Mounjaro is an alternative GLP-1 injection, and Foundayo is the oral GLP-1 option. The next step, in every case, is a proper consultation with an endocrinologist.
Book a GLP-1 weight-loss consultation at Endocare in Dubai or Abu Dhabi. The initial specialist consultation is AED 700 and includes a full clinical assessment, review of recent labs, and a body-composition analysis, so the recommendation you leave with is built on your actual medical picture.
